Kingswood Resources

Reports

MIRA Pharmaceuticals Reports Q3 2025 Results

November 17, 2025

KAREN STERLING, PhD, CFA

Download Report

MIRA Pharmaceuticals Reports Q2 2025 Results

August 18, 2025

KAREN STERLING, PhD, CFA

Download Report

Perspective on MIRA Pharmaceuticals’s Acquisition of SKNY Pharmaceuticals

May 23, 2025

KAREN STERLING, PhD, CFA

Download Report

MIRA Pharmaceuticals Reports Q1 2025 Results

May 19, 2025

KAREN STERLING, PhD, CFA

Download Report

MIRA Pharmaceuticals Reports FY 2024 Results

April 4, 2025

KAREN STERLING, PhD, CFA

Download Report

MIRA Pharmaceuticals Announces Upcoming Start of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

March 5, 2025

KAREN STERLING, PhD, CFA

Download Report

MIRA Pharmaceuticals Files Investigational New Drug Application for Ketamir-2 with FDA

December 20, 2024

KAREN STERLING, PhD, CFA

Download Report

MIRA Pharmaceuticals Reports Third Quarter 2024 Earnings

November 14, 2024

KAREN STERLING, PhD, CFA

Download Report

MIRA Pharmaceuticals Announces Superiority of Ketamir-2 to Gabapentin (Neurontin) in Preclinical Studies

October 30, 2024

KAREN STERLING, PhD, CFA

Download Report

MIRA Pharmaceuticals Files 10Q, Reports on Preclinical Progress with Ketamir-2

August 27, 2024

KAREN STERLING, PhD, CFA

Download Report

MIRA Pharmaceuticals on Track to Advance Its Two Preclinical Assets Toward Clinical Trials

July 24, 2024

KAREN STERLING, PhD, CFA

Download Report

Engineering Cannabinoids to Treat Neurodegenerative Diseases and Chronic Pain

April 19, 2024

KAREN STERLING, PhD, CFA

Download Report

Engineering Cannabinoids to Treat Neurodegenerative Diseases and Chronic Pain

January 31, 2024

KAREN STERLING, PhD, CFA

Download Report